Key indicators: powder synchrotron study; T = 293 K; mean (C-C) = 0.004 Å; disorder in main residue; R factor = 0.055; wR factor = 0.074; data-to-parameter ratio = 5.5.
In the title compound [systematic name 5-deoxy-5-fluoro-N-(pentyloxycarbonyl)cytidine], C 15 H 22 FN 3 O 6 , the pentyl chain is disordered over two positions with refined occupancies of 0.53 (5) and 0.47 (5). The furan ring assumes an envelope conformation. In the crystal, intermolecular N-HÁ Á ÁO hydrogen bonds link the molecules into chains propagating along the b axis. The crystal packing exhibits electrostatic interactions between the 5-fluoropyrimidin-2(1H)-one fragments of neighbouring molecules as indicated by short OÁ Á ÁC 
Related literature
Capecitabine is the first FDA-approved oral chemotherapy for the treatment for some types of cancer, including advanced bowel cancer or breast cancer, see: Wagstaff et al. (2003) ; Jones et al. (2004) .
Experimental
Crystal data Hydrogen-bond geometry (Å , ). 
Comment
Capecitabine is the first FDA-approved oral chemotherapy for the treatment for some types of cancer, including advanced bowel cancer or breast cancer (Wagstaff et al., 2003; Jones et al., 2004) . Capecitabine is 5-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine and in vivo is enzymatically converted to the active drug 5-fluorouracil. Crystal structure determination of capecitabine was not reported yet. In this paper we report crystal structure determination of the title compound from the powder diffraction data by using synchrotron radiation.
The asymmetric unit consists of one molecule of capecitabine (Fig 1) . The crystal packing is stabilized by intermolecular interactions -electrostatic interactions proved by short O···C and F···C contacts (Table 1) and N-H···O hydrogen bonds (Table 2) .
Experimental
Samples of crystalline capecitabine were prepared by two methods, a and b, respectively. Method a: capecitabine (10 g) was dissolved in EtOH (80 g). The solution was concentrated under reduced pressure to a residual volume of 25 ml and kept under stirring overnight. The solid was filtered off and dried at room temperature furnishing capecitabine (6 g). Method b:
capecitabine (18 g) was dissolved in DCM (200 g) and the solution was evaporated to dryness under reduced pressure. The residue was taken up with toluene (400 g) and about 150 g of solvent were distilled off. The solution was heated up to 50°C and then allowed to 3 spontaneously cool to 25°C. After cooling to 0°C, the solid was filtered off, washed with toluene and dried at 60°C under vacuum to constant weight furnishing capecitabine (16.5 g).
Refinement
Both crystallization procedures lead to one polycrystalline form of capecitabine. It was confirmed by measuring on X-Ray powder diffractometer PANalytical Xpert Pro, Cu Kα radiation (λ = 1.541874 Å). Attempts to determine the structure from these data were unsuccessful probably due to flexible molecule of capecitabine and low resolution of these data. The powder obtained by the first "a" procedure was used for structure determination. X-Ray diffraction data were collected on the high resolution diffractometer ID31 of the European Synchrotron Radiation Facility. The monochromatic wavelength was fixed at 0.79483 (4) Å. Si (111) crystal multi-analyser combined with Si (111) monochromator was used (beam offset angle α = 2°). A rotating 1-mm-diameter borosilicate glass capillary with capecitabine powder was used for the experiment. Data were measured from 1.002°2θ to 34.998°2θ at the room temperature, steps scans was set to 0.003°2θ. et al., 1985) . For the solution process hydrogen atoms were removed. This model was restrained with bonds and angles restraints, automatically generated by program
FOX. The refinement was carried out in GSAS (Larson & Von Dreele, 1994) . Hydrogen atoms were added in positions based on geometry and structure was restrained by bonds and angles restraints. Five planar restraints for sp 2 hybridization were used (O20/C18/O19/N17, N17/C13/N14/C12, C13/C12/F16/C11, N14/C10/O15/N9 and C4/N9/C10/C11). Due to relatively high U iso thermal parameters of alkyl chain (C21-C25) the structure was refined with two disordered chains (C21-C25 and C21a-C25a) with occupancy factors 0.53 (5) and 0.47 (5). U iso thermal parameters were constrained just for atoms in disordered chains by this way (C21/C21a, C22/C22a, C23/C23a, C24/C24a, C25/C25a). At the final stage atomic coordinates of non-hydrogen atoms were refined to the final agreement factors: R p =0.055 and R wp =0.0743. The diffraction profiles and the differences between the measured and calculated profiles are shown in Fig. 2 . Figures   Fig. 1 . The molecular structure of capecitabine showing the atomic numbering. Displacement spheres are drawn at the 20% probability level. Only major part of the disordered pentyl chain is shown. 
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